Education
About Us
Working with TipRanks
Follow Us
Alpha Cognition Inc (ACOG)
NASDAQ:ACOG
ACOG Stock Chart & Stats
$5.81
<$0.01(0.02%)
At close: 4:00 PM EST
$5.81
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$3.75 - $11.54
Previous Close$5.43
Volume265.46K
Average Volume (3M)97.92K
Market Cap
$124.36M
Enterprise Value$69.64M
Total Cash (Recent Filing)$35.40M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Apr 07, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding21,742,104
10 Day Avg. Volume48,734
30 Day Avg. Volume97,921
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-5.49
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue9.38
Enterprise Value/Gross Profit12.83
Enterprise Value/Ebitda-3.74
Forecast
1Y Price Target
$18.00Price Target Upside209.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAlpha Cognition reported a 3Q25 net loss of only $0.08 per share vs. the estimate for a net loss of $0.39 per share.
Market PenetrationTotal 3Q25 prescribers surpassed 500, representing 55% growth over the prior quarter.
Product Sales GrowthAlpha Cognition has reported continued progress with the commercial rollout of its marketed product ZUNVEYL, which achieved 102% quarter-over-quarter growth in pharmacy orders.
Bears Say
Price Target AdjustmentThe 12-month price target was reduced to $18 from $20 to account for the equity dilution from the most recent financing.
Revenue DeclineThe full-year 2025 net sales forecast has been decreased to $5.7M from the prior $11.7M to reflect slower contracting and reimbursement.
Sales Forecast RevisionThe full-year 2025 net sales forecast has been decreased to reflect slower contracting and reimbursement.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $3.75 and its highest was $11.54 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $124.36M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Apr 07, 2026 which is in 124 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on Nov 13, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.35.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -0.26.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 21,742,104 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went down -3.1%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
Alpha Cognition Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (209.81% Upside)
$18.00 (209.81% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 16.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.65%
12-Months-Change
Fundamentals
Return on Equity
-125.65%
Trailing 12-Months
Asset Growth
820.85%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc (ACOG) is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company primarily operates in the biotechnology and healthcare sectors, with its core products being novel therapies aimed at addressing conditions such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Alpha Cognition's innovative approach involves the development of both small molecules and biologics to create effective and safe treatment options for patients affected by these debilitating disorders.
ACOG Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong positive momentum with significant growth in ZUNVEYL sales and market engagement, supported by a solid financial position. However, challenges such as operating losses and limited payer coverage remain.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$18.00
▲(209.81% Upside)
Technical Analysis
Sangamo Biosciences
―
Elicio Therapeutics
―
Cognition Therapeutics
―
Lucid Diagnostics
―
Nuvectis Pharma
―
Ownership Overview
2.78% Insiders
0.06% Mutual Funds
23.72% Other Institutional Investors
73.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---